References
- Graybill JR, Revankar SG, Patterson TF. Systemic antifungal drugs in current use. In: Aiello, L, Hay, RD, eds. Topley & Wilson's Microbiology and Microbial Infections, 9th edn. London: Arnold, 1998: 163–165.
- Kauffman CA, Carver PL. Antifungal agents in the 1990s. Current status and future developments. Drugs 1997; 53: 539–549.
- Gains HA. Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Clin Infect Dis 1996; 22 (Suppl. 2): S145–S147.
- Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother 2000; 12: 463–470.
- Viviani MA, De Marie S, Graybill JR, et al. New approaches to antifungal chemotherapy. Med Mycol 1998; 36: 194–206.
- Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 1999; 19: 306–323.
- Dix SP, Andriole VT. Lipid formulations of amphotericin B. Curr Clin Top Infect Dis 2000; 20: 1–23.
- Robinson RF, Nahata MC. A comparative review of conven-tional and lipid formulations of amphotericin B. J Gun Pharm Therap 1999; 24: 249–257.
- Shadkchan Y, Segal E, Bor A, et al. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. J Antimicrob Chemother1997; 39: 655–658.
- Shadkchan Y, Segal E. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice. J Antimicrob Chemother 1999; 44: 787–790.
- Shadkchan Y, Segal E. Treatment of experimental candidosis with amphotericin B-intralipid admixtures in compromised mice. J Antimicrob Chemother 2001; 48: 245–251.
- Barenholz Y, Cohen R. Rational design of amphiphile-based drug carriers and sterically stabilized carriers. J Liposom Res 1995; 5: 905–932.